Ipsen, a globally active biopharmaceutical company listed in Paris and in the U.S., has entered into a definitive share purchase agreement to acquire all issued and outstanding shares of Memo Therapeutics, a late-stage biotech
Tags :Ipsen
Ipsen, a globally active biopharmaceutical company listed in Paris and in the U.S., has entered into a definitive share purchase agreement to acquire all issued and outstanding shares of Memo Therapeutics, a late-stage biotech
